Exploring the Relationship Between Daratumumab Treatment and Stem Cell Collection in Newly Diagnosed Multiple Myeloma (NDMM) Patients Undergoing Transplantation: Insights From a Single-Center Investigation.

IF 0.6 4区医学 Q4 HEMATOLOGY

Indian Journal of Hematology and Blood Transfusion Pub Date : 2025-10-01 Epub Date: 2024-11-14 DOI:10.1007/s12288-024-01914-8

Durga Chougule, Geet Aggarwal, Nitin Sood, Aseem Kumar Tiwari, Padam Singh, Manish Kumar Singh

{"title":"Exploring the Relationship Between Daratumumab Treatment and Stem Cell Collection in Newly Diagnosed Multiple Myeloma (NDMM) Patients Undergoing Transplantation: Insights From a Single-Center Investigation.","authors":"Durga Chougule, Geet Aggarwal, Nitin Sood, Aseem Kumar Tiwari, Padam Singh, Manish Kumar Singh","doi":"10.1007/s12288-024-01914-8","DOIUrl":null,"url":null,"abstract":"Purpose: Daratumumab-induction regimen has benefitted the multiple myeloma patients with long-lasting effective response. However, studies have showed daratumumab induction therapy reduced CD34+ stem cell yield and increased dependence on plerixafor use during mobilization therapy for subsequent autologous stem cell transplantation (ASCT). Here, we aim to explore the influence of daratumumab-based induction therapy on CD34+ stem cell yield in Indian multiple myeloma patients.Methods: In this retrospective study, electronic medical records of transplant eligible multiple myeloma patients (n = 91) between December 2015 and February 2023 were considered. Clinical information about induction therapy, mobilization therapy, stem cell collection and transplant status were collected. Data analysis was done using SPSS v.26, with statistical significance at p < 0.05.Results: Among the 91 patients, 8 received daratumumab induction regimen. The CD34+ stem cell yield among daratumumab and non-daratumumab induction groups did not show significant difference (5.29 ± 1.64 × 106 versus 6.08 ± 3.11 × 106 CD34+ cells/kg; p = 0.101). Patients on daratumumab induction regimen exhibited an increased use of plerixafor when compared to non-daratumumab induction regimen (p < 0.001).Conclusion: The addition of daratumumab in induction therapy of multiple myeloma did not affect stem cell yield but increased dependence on plerixafor during mobilization therapy.","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"41 4","pages":"942-946"},"PeriodicalIF":0.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12515134/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Hematology and Blood Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12288-024-01914-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/14 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Daratumumab-induction regimen has benefitted the multiple myeloma patients with long-lasting effective response. However, studies have showed daratumumab induction therapy reduced CD34+ stem cell yield and increased dependence on plerixafor use during mobilization therapy for subsequent autologous stem cell transplantation (ASCT). Here, we aim to explore the influence of daratumumab-based induction therapy on CD34+ stem cell yield in Indian multiple myeloma patients.

Methods: In this retrospective study, electronic medical records of transplant eligible multiple myeloma patients (n = 91) between December 2015 and February 2023 were considered. Clinical information about induction therapy, mobilization therapy, stem cell collection and transplant status were collected. Data analysis was done using SPSS v.26, with statistical significance at p < 0.05.

Results: Among the 91 patients, 8 received daratumumab induction regimen. The CD34+ stem cell yield among daratumumab and non-daratumumab induction groups did not show significant difference (5.29 ± 1.64 × 10⁶ versus 6.08 ± 3.11 × 10⁶ CD34+ cells/kg; p = 0.101). Patients on daratumumab induction regimen exhibited an increased use of plerixafor when compared to non-daratumumab induction regimen (p < 0.001).

Conclusion: The addition of daratumumab in induction therapy of multiple myeloma did not affect stem cell yield but increased dependence on plerixafor during mobilization therapy.

查看原文本刊更多论文

探索达拉单抗治疗与接受移植的新诊断多发性骨髓瘤（NDMM）患者干细胞收集之间的关系：来自单中心研究的见解

目的：daratumumab诱导方案使多发性骨髓瘤患者受益，并具有持久的有效反应。然而，研究表明，在随后的自体干细胞移植（ASCT）的动员治疗中，daratumumab诱导治疗降低了CD34+干细胞的产量，增加了对plerixa使用的依赖性。在这里，我们的目的是探讨基于daratumumab的诱导治疗对印度多发性骨髓瘤患者CD34+干细胞产量的影响。方法：回顾性研究2015年12月至2023年2月期间符合移植条件的多发性骨髓瘤患者（n = 91）的电子病历。收集诱导治疗、动员治疗、干细胞采集及移植情况的临床资料。使用SPSS v.26进行数据分析，p值有统计学意义。结果：91例患者中，8例患者接受了daratumumab诱导方案。达拉单抗诱导组和非达拉单抗诱导组的CD34+干细胞产量无显著差异（5.29±1.64 × 106 vs 6.08±3.11 × 106 CD34+细胞/kg， p = 0.101）。结论：在多发性骨髓瘤诱导治疗中加入daratumumab并不影响干细胞产量，但在动员治疗期间增加了对plerixafor的依赖。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian Journal of Hematology and Blood Transfusion HEMATOLOGY-

CiteScore

1.70

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Indian Journal of Hematology and Blood Transfusion is a medium for propagating and exchanging ideas within the medical community. It publishes peer-reviewed articles on a variety of aspects of clinical hematology, laboratory hematology and hemato-oncology. The journal exists to encourage scientific investigation in the study of blood in health and in disease; to promote and foster the exchange and diffusion of knowledge relating to blood and blood-forming tissues; and to provide a forum for discussion of hematological subjects on a national scale. The Journal is the official publication of The Indian Society of Hematology & Blood Transfusion.